3 years ago

CV6 Therapeutics Raises $9.2 Million to Advance Cancer Treatment

  • CV6 Therapeutics, a Belfast-based drug development biotechnology company, has secured $9.2 million in funding

  • Backers include QUBIS, Invest Northern Ireland, CoFund NI, and Techstart Ventures

  • The company plans to use the funds to advance its oncology asset CV6-168 into a Phase 1a clinical trial and continue scientific development work

  • CV6-168 is a unique cancer therapeutic that targets uracilation of cancer cell DNA, leading to cell death and immune system stimulation.

      • ProblemHealthcare

      "Cancer is a major global health problem, and there is a need for new and effective therapies to treat it."

      Solution

      "CV6 Therapeutics is developing a new drug, CV6-168, which is a small molecule therapeutic that targets uracilation in cancer cells. This drug has shown promising results in preclinical studies and is now moving into a Phase 1a clinical trial."

      Covered on